BR112022009560A2 - Células dendríticas hiperativas possibilitam imunidade antitumoral baseada na transferência de células adotivas duráveis - Google Patents

Células dendríticas hiperativas possibilitam imunidade antitumoral baseada na transferência de células adotivas duráveis

Info

Publication number
BR112022009560A2
BR112022009560A2 BR112022009560A BR112022009560A BR112022009560A2 BR 112022009560 A2 BR112022009560 A2 BR 112022009560A2 BR 112022009560 A BR112022009560 A BR 112022009560A BR 112022009560 A BR112022009560 A BR 112022009560A BR 112022009560 A2 BR112022009560 A2 BR 112022009560A2
Authority
BR
Brazil
Prior art keywords
dendritic cells
cell transfer
adoptive cell
antitumor immunity
cells enable
Prior art date
Application number
BR112022009560A
Other languages
English (en)
Inventor
C Kaganno Jonathan
Zhivaki Dania
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of BR112022009560A2 publication Critical patent/BR112022009560A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/051—Lipid A (MPA, MPL)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

CÉLULAS DENDRÍTICAS HIPERATIVAS POSSIBILITAM IMUNIDADE ANTITUMORAL BASEADA NA TRANSFERÊNCIA DE CÉLULAS ADOTIVAS DURÁVEIS. A presente invenção refere-se à imunoterapia de câncer, por exemplo, estimulação da terapia antitumoral mediada por células T.
BR112022009560A 2019-11-18 2020-11-18 Células dendríticas hiperativas possibilitam imunidade antitumoral baseada na transferência de células adotivas duráveis BR112022009560A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937075P 2019-11-18 2019-11-18
PCT/US2020/061132 WO2021102057A1 (en) 2019-11-18 2020-11-18 Hyperactive dendritic cells enable durable adoptive cell transfer-based anti-tumor immunity

Publications (1)

Publication Number Publication Date
BR112022009560A2 true BR112022009560A2 (pt) 2022-08-02

Family

ID=75981013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009560A BR112022009560A2 (pt) 2019-11-18 2020-11-18 Células dendríticas hiperativas possibilitam imunidade antitumoral baseada na transferência de células adotivas duráveis

Country Status (10)

Country Link
US (1) US20220401535A1 (pt)
EP (1) EP4061423A4 (pt)
JP (1) JP2023503427A (pt)
KR (1) KR20220116450A (pt)
CN (1) CN114980928A (pt)
AU (1) AU2020386007A1 (pt)
BR (1) BR112022009560A2 (pt)
CA (1) CA3163173A1 (pt)
IL (1) IL293034A (pt)
WO (1) WO2021102057A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2769326T3 (es) * 2010-02-05 2020-06-25 Univ Cornell Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor
EP3083945B1 (en) * 2013-12-18 2020-03-18 Julius-Maximilians-Universität Würzburg Galactose oxidase treatment of dendritic cells to improve their immunogenicity
AU2016206965B2 (en) * 2015-01-12 2021-03-04 Children's Medical Center Corporation Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
US20180127717A1 (en) * 2015-05-07 2018-05-10 Baylor College Of Medicine Dendritic cell immunotherapy
EP4041298A1 (en) * 2019-10-07 2022-08-17 NorthWest Biotherapeutics, Inc. In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response

Also Published As

Publication number Publication date
JP2023503427A (ja) 2023-01-30
CN114980928A (zh) 2022-08-30
KR20220116450A (ko) 2022-08-23
CA3163173A1 (en) 2021-05-27
IL293034A (en) 2022-07-01
EP4061423A1 (en) 2022-09-28
WO2021102057A1 (en) 2021-05-27
AU2020386007A1 (en) 2022-06-02
EP4061423A4 (en) 2023-12-06
US20220401535A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
CO2019004630A2 (es) Composiciones de células t con car anti-bcma
MX2017017049A (es) Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados.
BR112015027567A2 (pt) polipeptídeo, sequência de ácido nucleico isolada, célula, método de fornecimento de uma imunidade antitumoral
NZ765695A (en) Immune cell organoid co-cultures
BR112017009475A2 (pt) métodos de seleção de uma linhagem de células t e de um doador das mesmas para terapia celular adotiva
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
MX2019011897A (es) Celulas efectoras inmunitarias especificas de antigenos.
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
MX2017005250A (es) Metodos para tratar infecciones por el virus de filoviridae.
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
BR112018009393A8 (pt) produção microbiana de nicotinamida ribosídeo
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
MX2018003463A (es) Método de redireccionamiento de células t para tratar la infección por virus de inmunodeficiencia humana (vih).
MX2018011666A (es) Combinaciones farmaceuticas para el tratamiento de cancer.
BR112016013845A2 (pt) Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças
CL2021002067A1 (es) Células modificadas por receptor de antígeno quimérico para el tratamiento de cánceres que expresan cldn6.
BR112021017744A2 (pt) Composições e métodos de cd40l para regulação ajustável
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
BR112021021608A2 (pt) Células car-t direcionadas a cd19 específicas para antígeno
WO2018140850A3 (en) T cells derived from umbilical cord blood